What is HC Wainwright's Estimate for EPRX Q3 Earnings?

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Eupraxia Pharmaceuticals to ($0.22), down from ($0.20), while maintaining a "Buy" rating and a price target of $12.00.
• The average rating for Eupraxia Pharmaceuticals is currently "Moderate Buy", with a consensus price target of $11.00 among analysts.
• Eupraxia Pharmaceuticals reported a Q2 EPS of ($0.26), which was lower than the analysts' consensus estimate of ($0.21).

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Stock analysts at HC Wainwright cut their Q3 2025 EPS estimates for Eupraxia Pharmaceuticals in a research note issued to investors on Thursday, October 2nd. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.20). HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals' current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.55) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.13) EPS.

Several other brokerages have also weighed in on EPRX. Weiss Ratings restated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a report on Saturday, September 27th. Canaccord Genuity Group began coverage on Eupraxia Pharmaceuticals in a research report on Monday, June 16th. They set a "speculative buy" rating on the stock. Finally, Cantor Fitzgerald started coverage on Eupraxia Pharmaceuticals in a research note on Thursday, July 24th. They issued an "overweight" rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Eupraxia Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX stock opened at $5.85 on Monday. The firm has a market capitalization of $210.37 million, a PE ratio of -6.88 and a beta of 1.51. Eupraxia Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $7.19. The stock has a fifty day moving average of $5.48 and a two-hundred day moving average of $4.59.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05).

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in EPRX. Scotia Capital Inc. boosted its position in Eupraxia Pharmaceuticals by 11.6% during the 1st quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock worth $5,072,000 after acquiring an additional 160,960 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock worth $1,125,000 after acquiring an additional 59,683 shares during the period. Ingalls & Snyder LLC bought a new position in Eupraxia Pharmaceuticals during the 2nd quarter worth $214,000. JPMorgan Chase & Co. boosted its holdings in Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company's stock valued at $108,000 after purchasing an additional 16,017 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock valued at $72,000 after buying an additional 10,059 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.